Ariad halts Iclusig trial enrollment on blood-clot worries

Lingering safety concerns about Ariad Pharmaceuticals' ($ARIA) blockbuster leukemia drug Iclusig (ponatinib) boiled up into a crisis today. After investigators tracked a rising rate of blood clots among leukemia patients in ongoing clinical studies, the biotech slammed the brakes on new trial enrollment and rolled out a lower dosing schedule for current participants. Report